Kristi A. Boehm

Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735

Stephen E. Jones, Frankie A. Holmes, Joyce O’Shaughnessy et al. · Journal of Clinical Oncology · 2009 · 584 citations

Phase III Trial Comparing Doxorubicin Plus Cyclophosphamide With Docetaxel Plus Cyclophosphamide As Adjuvant Therapy for Operable Breast Cancer

Stephen E. Jones, Michael A. Savin, Frankie A. Holmes et al. · Journal of Clinical Oncology · 2006 · 537 citations · Full text

Randomized Phase III Trial of Gemcitabine-Based Chemotherapy With In Situ RRM1 and ERCC1 Protein Levels for Response Prediction in Non–Small-Cell Lung Cancer

Craig H. Reynolds, Coleman K. Obasaju, Michael J. Schell et al. · Journal of Clinical Oncology · 2009 · 172 citations · Full text

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy

Guru Sonpavde, Phillip Periman, D. M. Bernold et al. · Annals of Oncology · 2009 · 137 citations · Full text

Urology, Sunitinib Malate, Genitourinary Cancer +6

Gemcitabine plus CI-994 offers no advantage over gemcitabine alone in the treatment of patients with advanced pancreatic cancer: results of a phase II randomized, double-blind, placebo-controlled, multicenter study

David Richards, Kristi A. Boehm, David Waterhouse et al. · Annals of Oncology · 2006 · 98 citations · Full text

Urology, Pancreatic Cancer, Phase Ii +10